Novo Nordisk Crash: Is Wegovy Failing?

Novo Nordisk just suffered its worst single-day drop in history—falling 25%—after slashing its 2025 sales and profit forecast tied to its flagship weight-loss drug Wegovy. The pharmaceutical giant is facing serious headwinds, including over 1 million U.S. patients using cheaper, compounded versions of semaglutide. Novo has filed lawsuits against telehealth companies like Hims & Hers, but the damage may already be done. With shares down 65% from their 2023 peak, analysts now question whether the weight-loss drug trade is topping out. Watch this breakdown to understand what’s really happening—and what it could mean for the future of obesity drugs, investors, and the healthcare industry. 🌐 Want more market-moving insights? Dive deeper at www.benzinga.com — your one-stop destination for the latest financial news, data, and expert analysis to stay ahead of the markets. 📲 Let’s stay connected! Follow us for real-time updates, market tips, and exclusive content: 🔹 Instagram: https://www.instagram.com/benzinga 🔹 Facebook: https://www.facebook.com/benzinga 🔹 TikTok: https://www.tiktok.com/@benzinga 🔹 X: https://www.x.com/benzinga ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #wegovy #stockmarket #novonordisk